Regencell Bioscience Holdings (RGC) Operating Leases (2022 - 2025)

Regencell Bioscience Holdings has reported Operating Leases for 4 years, with the latest figure at $128178.0 in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases changed N/A year-over-year to $128178.0; the trailing twelve-month figure through Dec 2025 stood at $128178.0 (changed N/A YoY), and the FY2025 full-year result was $231635.0, up 793.17% from the prior year.
• Operating Leases for Q4 2025 stood at $128178.0, down from $231635.0 in the prior quarter.
• The five-year high for Operating Leases was $360268.0 in Q2 2022, with the low at $25406.0 in Q2 2023.
• Historically, Operating Leases has averaged $154284.2 across 4 years, with a median of $128178.0 in 2025.
• Annual changes were most pronounced in 2023 — Operating Leases tumbled 92.95% — and 2025, when it jumped 793.17%.
• Regencell Bioscience Holdings' Operating Leases stood at $360268.0 in 2022, then plunged by 92.95% to $25406.0 in 2023, then increased by 2.08% to $25934.0 in 2024, then jumped by 394.25% to $128178.0 in 2025.
• The last three Operating Leases figures came in at $128178.0 (Q4 2025), $231635.0 (Q2 2025), and $25934.0 (Q2 2024), per Business Quant data.